Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...

Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...

HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO) reported fourth-quarter results that fell short of analyst expectations, sending shares down 4% in after-hours trading Thursday. The life ...

We recently published a list of Billionaire Mason Hawkins’ 10 Small-Cap Stocks with Huge Upside Potential. In this article, we are going to take a look at where Bio-Rad Laboratories, Inc. (NYSE:BIO) ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...

RBC Capital lowered the firm’s price target on Bio-Rad (BIO) to $409 from $430 and keeps an Outperform rating on the shares as part of a broader research note previewing Q1 results in the Life Science ...

We recently compiled a list of the 7 Best Medical Technology Stocks To Buy According To Analysts. In this article, we are going to take a look at where Bio-Rad Laboratories, Inc. (NYSE:BIO) stands ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report) on April 1 and set a price target of $430.00. The company’s shares closed yesterday at ...